Artivion, Inc. Hits New 52-Week High of $47.69, Up 104%

Artivion, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 47.69 on November 6, 2025. This achievement marks a remarkable 104.13% increase in the company's stock price over the past year, significantly outperforming the S&P 500, which has seen a gain of 17.53% during the same period.
With a market capitalization of USD 2,114 million, Artivion operates in a competitive industry characterized by innovation and rapid advancements. The company's financial metrics reveal a debt-to-equity ratio of 0.40, indicating a manageable level of debt relative to its equity. However, it is important to note that Artivion is currently loss-making, as reflected by its negative return on equity of -1.88%.

The stock's previous 52-week low was recorded at USD 21.97, highlighting the substantial growth it has experienced in the past year. As Artivion continues to navigate the dynamic landscape of the pharmaceuticals and biotechnology industry, this new high underscores its evolving market position.